The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio (Q46634193)
Jump to navigation
Jump to search
scientific article published in November 2005
Language | Label | Description | Also known as |
---|---|---|---|
English | The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio |
scientific article published in November 2005 |
Statements
1 reference
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio (English)
1 reference
1 reference
Terpos E
1 reference
Mihou D
1 reference
Tsimirika K
1 reference
Karkantaris C
1 reference
Politou M
1 reference
Voskaridou E
1 reference
Rahemtulla A
1 reference
Zervas K
1 reference
1 November 2005
1 reference
1 reference
19
1 reference
11
1 reference
1969-1976
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference